AU2001267864A1 - Remedial agent for optic nerve disease and the like - Google Patents

Remedial agent for optic nerve disease and the like

Info

Publication number
AU2001267864A1
AU2001267864A1 AU2001267864A AU6786401A AU2001267864A1 AU 2001267864 A1 AU2001267864 A1 AU 2001267864A1 AU 2001267864 A AU2001267864 A AU 2001267864A AU 6786401 A AU6786401 A AU 6786401A AU 2001267864 A1 AU2001267864 A1 AU 2001267864A1
Authority
AU
Australia
Prior art keywords
optic nerve
nerve disease
remedial agent
medicament
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267864A
Inventor
Eri Inoue
Tomiya Mano
Shunji Sogou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tokyo Pharmaceuticals Inc
Original Assignee
Mitsubishi Tokyo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tokyo Pharmaceuticals Inc filed Critical Mitsubishi Tokyo Pharmaceuticals Inc
Publication of AU2001267864A1 publication Critical patent/AU2001267864A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
AU2001267864A 2000-06-29 2001-06-28 Remedial agent for optic nerve disease and the like Abandoned AU2001267864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-197250 2000-06-29
JP2000197250 2000-06-29
PCT/JP2001/005585 WO2002000260A1 (en) 2000-06-29 2001-06-28 Remedial agent for optic nerve disease and the like

Publications (1)

Publication Number Publication Date
AU2001267864A1 true AU2001267864A1 (en) 2002-01-08

Family

ID=18695597

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267864A Abandoned AU2001267864A1 (en) 2000-06-29 2001-06-28 Remedial agent for optic nerve disease and the like

Country Status (8)

Country Link
US (2) US20030109566A1 (en)
EP (1) EP1297849B1 (en)
JP (1) JPWO2002000260A1 (en)
AT (1) ATE428470T1 (en)
AU (1) AU2001267864A1 (en)
CA (1) CA2414586C (en)
DE (1) DE60138385D1 (en)
WO (1) WO2002000260A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211596B2 (en) 2001-05-11 2007-05-01 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
CA2484512C (en) 2002-05-17 2013-04-16 Othera Pharmaceuticals, Inc. Treatment of cataracts and other ophthalmic diseases
DE60239165D1 (en) * 2002-11-05 2011-03-24 Lead Chem Co Ltd PERCUTANEOUS ABSORPTION PREPARATIONS WITH 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ON
US7825134B2 (en) 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
CN101102770A (en) * 2003-11-20 2008-01-09 奥特拉药物公司 Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2007055312A1 (en) * 2005-11-10 2007-05-18 Mitsubishi Tanabe Pharma Corporation Plastic container filled with aqueous solution containing pyrazolone compound
US8168670B2 (en) * 2007-11-21 2012-05-01 Teikoku Pharma Usa, Inc. Pyrazolone derivative emulsion formulations
JP5591720B2 (en) 2009-01-29 2014-09-17 株式会社林原 Anti-neurodegenerative disease agent
JP2017222575A (en) 2014-09-19 2017-12-21 田辺三菱製薬株式会社 Preventive and therapeutic agent for ophthalmologic disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533662A1 (en) * 1984-09-20 1986-03-27 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Combination of 1-phenyl-4-alkylpyrazolidine-3,5-dione derivatives with a strong reducing agent for producing a topical antiinflammatory drug for eyes
JPS62108814A (en) 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd Inhibitor against formation of peroxide lipide
JPS61263917A (en) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk Cerebral function normalizing agent
DK169672B1 (en) * 1985-05-20 1995-01-09 Mitsubishi Chem Ind Pharmaceutical preparations containing pyrazolone derivatives as active ingredient and the use of pyrazolone derivatives for the preparation of pharmaceutical preparations
FR2608045B1 (en) 1986-12-12 1990-03-02 Chauvin Laboratoires USE OF XANTHINE OXIDASE INHIBITORS, OXYGEN FREE RADIAL TRAPERS AND IRON CHELATORS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA
JP2906512B2 (en) * 1990-01-16 1999-06-21 三菱化学株式会社 Anti-ulcer agent
WO1993000088A1 (en) * 1991-06-24 1993-01-07 Hoechst Aktiengesellschaft Use of phenylpyrazoline derivatives for the treatment of elevated intraocular pressure
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
JPH0725765A (en) * 1993-07-07 1995-01-27 Mitsubishi Chem Corp Agent for ophthalmic disease
JPH09278652A (en) * 1996-04-05 1997-10-28 Sumitomo Pharmaceut Co Ltd Retinal disease-treating preparation
GB9701710D0 (en) * 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
JPH10218771A (en) * 1997-02-05 1998-08-18 Ishihara Sangyo Kaisha Ltd Platelet-originating vascular endothelial cell growth factor inhibitor containing pyrazolone compound or its salt

Also Published As

Publication number Publication date
US20060247293A1 (en) 2006-11-02
CA2414586C (en) 2009-09-29
WO2002000260A1 (en) 2002-01-03
US20030109566A1 (en) 2003-06-12
JPWO2002000260A1 (en) 2004-01-08
EP1297849A1 (en) 2003-04-02
EP1297849A4 (en) 2006-10-18
EP1297849B1 (en) 2009-04-15
DE60138385D1 (en) 2009-05-28
CA2414586A1 (en) 2002-12-30
ATE428470T1 (en) 2009-05-15
US7638516B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
MX2007001679A (en) Prevention and treatment of synucleinopathic and amyloidogenic disease.
BR0210241A (en) Pyanoindazoles and their use in the treatment of glaucoma
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EA200400518A1 (en) METHODS OF TREATING EYE NONASCULAR DISEASES
WO2002058730A3 (en) Compositions for treatment of ocular neovascularization
GB0108592D0 (en) Therapeutic agents
WO2004004757A8 (en) Treatment for eye disorder
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
AU766216C (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
WO2002062385A3 (en) Method to prevent vision loss
EA200300560A1 (en) IMPROVED TREATMENT METHOD
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
CY1108983T1 (en) MYTHS OF PEROXIDE DIPHOMATISE FOR THE treatment of ophthalmic disorders and diseases
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
NO20042833L (en) Vaccine and method for treating motor neuronal disorders
BR0210238A (en) New Aryl-Amino-Propane Analogs and Their Use for the Treatment of Glaucoma
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
NO20044530L (en) Procedure for the treatment of cognitive disorders
BR0113201A (en) process for treating neurodegenerative disorders of the retina and optic nerve head
PT1131073E (en) USE OF ESTAUROSPORIN DERIVATIVES FOR THE TREATMENT OF NEOVASCULAR EYE DISEASES
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
EP1482922A4 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
BRPI0417549A (en) superoxide dismutase mimetics for the treatment of optic and retinal nerve injury